Atlas Trials

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

Clinical trial NCT07596524 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07596524
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Lung Cancer (NSCLC)
Start date
2026-07-01
Primary completion
2026-12-31
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.